Latest Breaking News On - Stephanl harris center - Page 1 : comparemela.com

A full dose of lurbinectedin plus a low dose of doxorubicin was clinically active and tolerable in patients with advanced or metastatic soft tissue sarcomas, supporting its continued investigation in those with leiomyosarcoma.

United statesKronos bioGregory michael coteSumitomo dainippon pharmaStephanl harris centerCancer centerJazz pharmaceuticalsHarvard medical schoolBelinda termeer centerMerck kgaaMerck kgaMassachusetts general hospitalTargeted therapiesConnective tissue oncologyHarvard medicalFoghorn therapeutics